Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AURA Aura Biosciences	$6.04 -1.0%	$5.85	$4.35 ▼ $12.38	$306.64M	0.42	210,777 shs	296,962 shs
CMPX Compass Therapeutics	$2.40 +0.8%	$2.07	$0.77 ▼ $4.08	$329.11M	1.41	956,472 shs	1.26 million shs
NTGN Neon Therapeutics	$3.07	$3.03	$0.88 ▼ $6.25	$88.93M	-0.81	516,108 shs	N/A
OCGN Ocugen	$1.06 -2.8%	$0.84	$0.52 ▼ $1.98	$318.31M	4.2	4.59 million shs	7.46 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AURA Aura Biosciences	-0.98%	-5.92%	+1.34%	-19.47%	-14.33%
CMPX Compass Therapeutics	+0.84%	-0.41%	+16.50%	+3.90%	+114.29%
NTGN Neon Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
OCGN Ocugen	-2.75%	-6.19%	+27.71%	+75.32%	-23.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AURA Aura Biosciences	1.767 of 5 stars	3.6	1.0	0.0	0.0	0.6	3.3	0.0
CMPX Compass Therapeutics	3.4236 of 5 stars	4.6	1.0	0.0	0.0	2.1	5.0	0.0
NTGN Neon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	1.4718 of 5 stars	3.5	1.0	0.0	0.0	3.2	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AURA Aura Biosciences	3.25	Buy	$22.00	264.24% Upside
CMPX Compass Therapeutics	3.11	Buy	$13.13	446.88% Upside
NTGN Neon Therapeutics	0.00	N/A	N/A	N/A
OCGN Ocugen	3.00	Buy	$6.00	466.04% Upside

Current Analyst Ratings Breakdown

Latest NTGN, AURA, CMPX, and OCGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$22.00
5/23/2025	AURA Aura Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$19.00
5/12/2025	OCGN Ocugen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
5/12/2025	OCGN Ocugen	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
5/9/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
4/28/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/22/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/21/2025	CMPX Compass Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
4/21/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/4/2025	CMPX Compass Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $24.00
4/2/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$3.04 per share	N/A
CMPX Compass Therapeutics	$850K	390.44	N/A	N/A	$0.91 per share	2.64
NTGN Neon Therapeutics	N/A	N/A	N/A	N/A	$0.50 per share	N/A
OCGN Ocugen	$4.05M	76.43	N/A	N/A	$0.10 per share	10.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AURA Aura Biosciences	-$86.92M	-$1.90	N/A	N/A	N/A	N/A	-58.63%	-49.74%	8/14/2025 (Estimated)
CMPX Compass Therapeutics	-$49.38M	-$0.41	N/A	N/A	N/A	N/A	-42.47%	-38.31%	8/11/2025 (Estimated)
NTGN Neon Therapeutics	-$79.78M	-$2.86	N/A	N/A	N/A	N/A	-199.09%	-137.14%	N/A
OCGN Ocugen	-$54.05M	-$0.19	N/A	N/A	N/A	-1,271.12%	-223.00%	-92.20%	8/6/2025 (Estimated)

Latest NTGN, AURA, CMPX, and OCGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	AURA Aura Biosciences	-$0.47	-$0.55	-$0.08	-$0.55	N/A	N/A
5/9/2025	Q1 2025	OCGN Ocugen	-$0.06	-$0.05	+$0.01	-$0.05	N/A	$1.48 million
5/8/2025	Q1 2025	CMPX Compass Therapeutics	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
3/24/2025	Q4 2024	AURA Aura Biosciences	-$0.43	-$0.52	-$0.09	-$0.52	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
NTGN Neon Therapeutics	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AURA Aura Biosciences	N/A	11.06	11.06
CMPX Compass Therapeutics	N/A	8.33	8.33
NTGN Neon Therapeutics	0.43	1.58	3.00
OCGN Ocugen	1.74	2.60	2.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AURA Aura Biosciences	96.75%
CMPX Compass Therapeutics	68.43%
NTGN Neon Therapeutics	54.71%
OCGN Ocugen	10.27%

Insider Ownership

Company	Insider Ownership
AURA Aura Biosciences	5.40%
CMPX Compass Therapeutics	29.80%
NTGN Neon Therapeutics	38.93%
OCGN Ocugen	4.42%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AURA Aura Biosciences	50	50.27 million	47.55 million	Not Optionable
CMPX Compass Therapeutics	20	138.28 million	97.08 million	Not Optionable
NTGN Neon Therapeutics	102	28.97 million	N/A	Not Optionable
OCGN Ocugen	80	292.03 million	279.12 million	Optionable

NTGN, AURA, CMPX, and OCGN Headlines

Recent News About These Companies

Ocugen: Three Potential Gene-Therapy Filings By 2028

June 18 at 4:18 PM | seekingalpha.com

Ocugen Receives FDA Clearance for Phase 2/3 Trial of Genetic Therapy for Stargardt Disease

June 17, 2025 | msn.com

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate ...

June 16, 2025 | gurufocus.com

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

June 16, 2025 | globenewswire.com

Bank of America Corp DE Sells 583,634 Shares of Ocugen, Inc. (NASDAQ:OCGN)

June 14, 2025 | marketbeat.com

Ocugen, Inc. to Present at 2025 BIO International Convention, Showcasing Gene Therapy Advancements for Blindness Diseases

June 11, 2025 | quiverquant.com

Ocugen To Present at BIO International Convention 2025

June 11, 2025 | globenewswire.com

Ocugen signs binding term sheet for license of OCU400 modifier gene therapy for retinitis pigmentosa in Korea

June 7, 2025 | pharmabiz.com

Ocugen Secures Licensing Agreement for OCU400 in Korea

June 6, 2025 | msn.com

Ocugen signs term sheet for korean licensing of OCU400 gene therapy

June 5, 2025 | ophthalmologytimes.com

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

June 5, 2025 | globenewswire.com

Jane Street Group LLC Purchases 357,891 Shares of Ocugen, Inc. (NASDAQ:OCGN)

June 1, 2025 | marketbeat.com

Ocugen’s OCU410ST receives Rare Pediatric Disease Designation for the treatment of ABCA4-associated retinopathies

May 27, 2025 | ophthalmologytimes.com

Ocugen wins FDA rare pediatric disease status for genetic eye disorder treatment

May 27, 2025 | msn.com

Ocugen, Inc. Receives FDA Rare Pediatric Disease Designation for OCU410ST in Treatment of ABCA4-Associated Retinopathies

May 27, 2025 | quiverquant.com

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

May 27, 2025 | globenewswire.com

The Analyst Verdict: Ocugen In The Eyes Of 5 Experts

May 14, 2025 | nasdaq.com

Ocugen Reports Progress in Q1 2025 with Advancements in Gene Therapy

May 13, 2025 | msn.com

1OCGN : The Analyst Verdict: Ocugen In The Eyes Of 5 Experts

May 13, 2025 | benzinga.com

Ocugen, Inc. (NASDAQ:OCGN) Q1 2025 Earnings Call Transcript

May 10, 2025 | msn.com

Ocugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns Bullish

May 9, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTGN, AURA, CMPX, and OCGN Company Descriptions

Aura Biosciences NASDAQ:AURA

$6.04 -0.06 (-0.98%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$6.02 -0.01 (-0.25%)

As of 06/20/2025 06:07 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Compass Therapeutics NASDAQ:CMPX

$2.40 +0.02 (+0.84%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.40 0.00 (-0.21%)

As of 06/20/2025 07:39 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Neon Therapeutics NASDAQ:NTGN

Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Ocugen NASDAQ:OCGN

$1.06 -0.03 (-2.75%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.05 -0.01 (-0.85%)

As of 06/20/2025 07:50 PM Eastern

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time